Department of Neurology, Klinikum Augsburg, Augsburg, Germany.
J Neurol Sci. 2013 Jan 15;324(1-2):53-6. doi: 10.1016/j.jns.2012.09.033. Epub 2012 Oct 23.
Lewis-Sumner syndrome (LSS, synonymous multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is a dysimmune peripheral neuropathy responding to corticosteroids and intravenous immunoglobulins (IVIG) in the majority of patients. We report on the long term treatment (37 and 46months respectively) of two LSS patients, who had initially responded to IVIG, with subcutaneous immunoglobulins (SCIg). Both were switched to SCIg since stabilization by IVIG could only be achieved with short treatment intervals, and one of them also suffered from recurrent transient ischemic attacks (TIAs) following IVIG related increased blood viscosity. Long-term use of SCIg was safe and well tolerated. Both patients were clinically stable with only mild to moderate fluctuations requiring SCIg dosage adaptions. No further ischemic events occurred, when the patient was switched to SCIg.
刘易斯-萨默尔综合征（Lewis-Sumner syndrome，LSS，同义词为多灶获得性脱髓鞘感觉运动神经病，MADSAM）是一种免疫介导的周围神经病，大多数患者对皮质类固醇和静脉注射免疫球蛋白（IVIG）有反应。我们报告了两名 LSS 患者的长期治疗（分别为 37 个月和 46 个月），这两名患者最初对 IVIG 有反应，后改用皮下免疫球蛋白（SCIg）。由于 IVIG 只能通过缩短治疗间隔来稳定病情，因此这两名患者都转为 SCIg 治疗，其中一名患者在 IVIG 相关的血液粘度增加后还出现复发性短暂性脑缺血发作（TIA）。长期使用 SCIg 是安全且耐受良好的。两名患者的临床状况均稳定，仅出现轻度至中度波动，需要调整 SCIg 剂量。当患者转为 SCIg 治疗时，没有发生进一步的缺血事件。
